Cargando…

New antibiotics for bad bugs: where are we?

Bacterial resistance to antibiotics is growing up day by day in both community and hospital setting, with a significant impact on the mortality and morbidity rates and the financial burden that is associated. In the last two decades multi drug resistant microorganisms (both hospital- and community-a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bassetti, Matteo, Merelli, Maria, Temperoni, Chiara, Astilean, Augusta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846448/
https://www.ncbi.nlm.nih.gov/pubmed/23984642
http://dx.doi.org/10.1186/1476-0711-12-22
_version_ 1782293429261172736
author Bassetti, Matteo
Merelli, Maria
Temperoni, Chiara
Astilean, Augusta
author_facet Bassetti, Matteo
Merelli, Maria
Temperoni, Chiara
Astilean, Augusta
author_sort Bassetti, Matteo
collection PubMed
description Bacterial resistance to antibiotics is growing up day by day in both community and hospital setting, with a significant impact on the mortality and morbidity rates and the financial burden that is associated. In the last two decades multi drug resistant microorganisms (both hospital- and community-acquired) challenged the scientific groups into developing new antimicrobial compounds that can provide safety in use according to the new regulation, good efficacy patterns, and low resistance profile. In this review we made an evaluation of present data regarding the new classes and the new molecules from already existing classes of antibiotics and the ongoing trends in antimicrobial development. Infectious Diseases Society of America (IDSA) supported a proGram, called “the ′10 × ´20′ initiative”, to develop ten new systemic antibacterial drugs within 2020. The microorganisms mainly involved in the resistance process, so called the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and enterobacteriaceae) were the main targets. In the era of antimicrobial resistance the new antimicrobial agents like fifth generation cephalosporins, carbapenems, monobactams, β-lactamases inhibitors, aminoglycosides, quinolones, oxazolidones, glycopeptides, and tetracyclines active against Gram-positive pathogens, like vancomycin-resistant S. aureus (VRSA) and MRSA, penicillin-resistant streptococci, and vancomycin resistant Enterococcus (VRE) but also against highly resistant Gram-negative organisms are more than welcome. Of these compounds some are already approved by official agencies, some are still in study, but the need of new antibiotics still does not cover the increasing prevalence of antibiotic-resistant bacterial infections. Therefore the management of antimicrobial resistance should also include fostering coordinated actions by all stakeholders, creating policy guidance, support for surveillance and technical assistance.
format Online
Article
Text
id pubmed-3846448
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38464482013-12-03 New antibiotics for bad bugs: where are we? Bassetti, Matteo Merelli, Maria Temperoni, Chiara Astilean, Augusta Ann Clin Microbiol Antimicrob Review Bacterial resistance to antibiotics is growing up day by day in both community and hospital setting, with a significant impact on the mortality and morbidity rates and the financial burden that is associated. In the last two decades multi drug resistant microorganisms (both hospital- and community-acquired) challenged the scientific groups into developing new antimicrobial compounds that can provide safety in use according to the new regulation, good efficacy patterns, and low resistance profile. In this review we made an evaluation of present data regarding the new classes and the new molecules from already existing classes of antibiotics and the ongoing trends in antimicrobial development. Infectious Diseases Society of America (IDSA) supported a proGram, called “the ′10 × ´20′ initiative”, to develop ten new systemic antibacterial drugs within 2020. The microorganisms mainly involved in the resistance process, so called the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and enterobacteriaceae) were the main targets. In the era of antimicrobial resistance the new antimicrobial agents like fifth generation cephalosporins, carbapenems, monobactams, β-lactamases inhibitors, aminoglycosides, quinolones, oxazolidones, glycopeptides, and tetracyclines active against Gram-positive pathogens, like vancomycin-resistant S. aureus (VRSA) and MRSA, penicillin-resistant streptococci, and vancomycin resistant Enterococcus (VRE) but also against highly resistant Gram-negative organisms are more than welcome. Of these compounds some are already approved by official agencies, some are still in study, but the need of new antibiotics still does not cover the increasing prevalence of antibiotic-resistant bacterial infections. Therefore the management of antimicrobial resistance should also include fostering coordinated actions by all stakeholders, creating policy guidance, support for surveillance and technical assistance. BioMed Central 2013-08-28 /pmc/articles/PMC3846448/ /pubmed/23984642 http://dx.doi.org/10.1186/1476-0711-12-22 Text en Copyright © 2013 Bassetti et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Bassetti, Matteo
Merelli, Maria
Temperoni, Chiara
Astilean, Augusta
New antibiotics for bad bugs: where are we?
title New antibiotics for bad bugs: where are we?
title_full New antibiotics for bad bugs: where are we?
title_fullStr New antibiotics for bad bugs: where are we?
title_full_unstemmed New antibiotics for bad bugs: where are we?
title_short New antibiotics for bad bugs: where are we?
title_sort new antibiotics for bad bugs: where are we?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846448/
https://www.ncbi.nlm.nih.gov/pubmed/23984642
http://dx.doi.org/10.1186/1476-0711-12-22
work_keys_str_mv AT bassettimatteo newantibioticsforbadbugswherearewe
AT merellimaria newantibioticsforbadbugswherearewe
AT temperonichiara newantibioticsforbadbugswherearewe
AT astileanaugusta newantibioticsforbadbugswherearewe